KLAS: Front-end speech tools benefits trump physician resistance

Laura Pedulli | | Health Exec | Precision Medicine

While physician resistance is cited by more than 50 percect of hospitals as the leading challenge to front-end speech (FES) deployment, 9 of out 10 hospitals indicated that they will nonetheless expand its use in their facilities, according to a study from KLAS.

The study, "Front-End Speech 2014: Functionality Doesn't Trump Physician Resistance," found that use of front-end speech software impacted every category measured in the study, including reduced transcription costs, reduced documentation time and more complete patient-narratives. Its conclusions reflected interviews of organizations using such software; vendors reviewed in the study included Dolbey, M*Modal and Nuance.

"Physicians are resistant to changes in their workflow. While hospital leadership sees the value of FES, many end-users are frustrated that they are now being asked to do the work of transcriptionists," said report author Boyd Stewart, KLAS research director, in a statement.

Access the report here.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.